Tirzepatide for Weight Loss
Tirzepatide (brand: Zepbound) is a once-weekly injectable medication used for weight loss and weight management, especially in adults with obesity or weight-related conditions like obstructive sleep apnea. It works by reducing appetite, increasing fullness, and slowing how quickly the stomach empties, which helps lower overall calorie intake.
Tirzepatide is a dual-action drug that targets both GIP and GLP-1 receptors, meaning it mimics natural hormones involved in blood sugar control and hunger regulation. It is self-administered under the skin using a pen or vial and is meant to be combined with a healthy diet and regular exercise.
Things to know about tirzepatide
-
FDA-approved for weight management in adults with obesity or overweight with related conditions
-
Prescription-only medication
-
Taken once weekly
-
Can lead to significant weight loss (up to ~22.5% over time in studies)
-
Not suitable for type 1 diabetes
Who Can Use It?
-
Adults with obesity
-
Adults who are overweight with related health conditions
-
Adults with obesity and severe obstructive sleep apnea
(Tirzepatide is also sold as Mounjaro for type 2 diabetes.)
How It Works
Tirzepatide activates both GIP and GLP-1 receptors, helping to:
-
Suppress appetite
-
Increase satiety (feeling full)
-
Slow digestion
-
Improve insulin response and sensitivity
-
Up to ~52 lbs (22.5%) average weight loss over 72 weeks at higher doses
-
Significantly greater weight loss compared to semaglutide in clinical trials
Side effects of Tirzepatide
-
Nausea
-
Diarrhea
-
Vomiting
-
Constipation
-
Fatigue
-
Injection site reactions
Serious Risks (Less Common)
-
Pancreatitis (severe abdominal pain)
-
Gallbladder issues
-
Kidney problems due to dehydration
-
Low blood sugar (especially with other diabetes meds)
-
Thyroid-related concerns
-
Allergic reactions
Overall, tirzepatide stands out due to its dual hormone action, making it one of the most effective options currently studied for weight loss and metabolic health.




Reviews
There are no reviews yet.